Literature DB >> 6347596

Third-generation and investigational cephalosporins: I. Structure-activity relationships and pharmacokinetic review.

P Garzone, J Lyon, V L Yu.   

Abstract

The structure-relationships and pharmacokinetic properties of the new second- and third-generation cephalosporins are reviewed. The new second-generation cephalosporins include ceforanide, cefotiam, and cefuroxime. The third-generation cephalosporins include cefmenoxime, cefoperazone, cefotaxime, cefsulodin, ceftazidime, ceftizoxime, ceftriaxone, and moxalactam. These new cephalosporins are semisynthetic analogs with different chemical substitutions on a 7-aminocephalosporanic nucleus. As a result of these chemical modifications, improvements in the antibacterial spectrum as well as pharmacokinetic properties have occurred. In general, the new cephalosporins have longer half-lives, higher and prolonged serum concentrations, and increased cerebrospinal fluid penetration. Selected cephalosporins also have increased biliary tract concentrations. A classification scheme for these new agents, based on generation and susceptibility to Pseudomonas aeruginosa, is presented.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6347596     DOI: 10.1177/106002808301700703

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  3 in total

Review 1.  The β-Lactams Strike Back: Ceftazidime-Avibactam.

Authors:  Evan J Zasowski; Jeffrey M Rybak; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2015-08       Impact factor: 4.705

2.  Penetration of cefoperazone into surgical wound drainage in patients undergoing head and neck surgery.

Authors:  R R Muder; V L Yu; J Johnson; P Thearle; J Lyon; W Diven
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

3.  Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.

Authors:  N J Khan; J A Bihl; R F Schell; J L LeFrock; S J Weber
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.